WTO 'expected to announce' 17-year drug patent waiver for LDCs

The World Trade Organization (WTO) is expected to announce a 17-year extension to an agreement that exempts the world’s Least Developed Countries (LDCs) from a duty to grant patents covering pharmaceutical drugs, an activist group has claimed.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

WTO fails to strike deal to waive COVID-19 IP

20 October 2020 Talks on a landmark proposal to waive IP rights for vaccines and treatments related to COVID-19 have stalled, following the failure of the World Trade Organisation to conclude an agreement.

Africa

WTO confirms 17-year extension to LDC patent waiver

6 November 2015 The World Trade Organization has granted permission for the world’s Least Developed Countries to be exempt from administering and enforcing patents directed to pharmaceutical drugs.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

WTO 'expected to announce' 17-year drug patent waiver for LDCs

More on this story

Editor's picks

Editor's picks

More features